MAPT and amyloidosis: The EV treatment produced a remarkable reduction in pathology, dampening proinflammatory gene programs in microglia (including the NF‐κB and NLRP3 inflammasome pathways), reducing reactive astrocyte changes, and leading to lower amyloid plaque burden and phosphorylated tau levels in the brain.